Development status: Approved, off-patent, not available in most countries

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to type II topoisomerases, gyrase and topoisomerase IV and thus, inhibits DNA cleavage and ligation reactions. It kills bacterial cells by increasing the concentration of enzyme–DNA cleavage complexes, thereby inhibiting cell replication.

Additional information: Synthetic naphthyridone. Progenitor of the quinolone antibitics. Renal elimination and little absorption after oral application.